We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00979134
Recruitment Status : Terminated (

Termination of study enrolment to Part C, Cohort 3 (08 July 2013) was based on the analysis of data from Study D2610C00004.

Data were available from 33 patient

)
First Posted : September 17, 2009
Results First Posted : March 15, 2019
Last Update Posted : March 15, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is primarily designed to assess the safety and tolerability of AZD4547 at increasing doses in patients with advanced solid malignancies and for whom no standard medication options are available. It also assesses the blood levels and action of AZD4547 in the body over a period of time.

Condition or disease Intervention/treatment Phase
Cancer Advanced Solid Malignancies Drug: AZD4547 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies
Actual Study Start Date : October 21, 2009
Actual Primary Completion Date : February 12, 2014
Actual Study Completion Date : March 5, 2015
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part A
Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
 Drug: AZD4547
Single dose is followed by washout 5-10 days before multiple dose
Experimental: Part B
Dose expansion phase, at the RD defined in Part A
 Drug: AZD4547
Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
Experimental: Part C
Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
 Drug: AZD4547
Patients start at a dose of 80 mg twice daily, with no washout


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Patients Who Experienced at Least 1 AE [ Time Frame: AEs are monitored from screenng through to 30 day follow up period ]
    To investigate the safety and tolerability of AZD4547. System organ class (SOC), preferred term (PT), duration and severity all recorded.

  2. Number of Participants Who Experienced at Least 1 Causally Related AE. [ Time Frame: AEs are continually assessed from screening up to 30 day FU period ]
    To investigate the safety and tolerability of AZD4547. A causally related AE is an AE deemed to be causally related to AZD4547.

  3. Number of Participants With at Least 1 AE of CTCAE >=G3 [ Time Frame: Ongoing up to discontinuation up to 30 day FU. ]
    To investigate the safety and tolerability of AZD4547

  4. Number of Participants With at Least 1 Causally Related AE of CTCAE >=G3 [ Time Frame: Ongoing up to discontinuation up to 30 day FU. ]
    To investigate the safety and tolerability of AZD4547

  5. Number of Participants Who Experienced at Least One SAE [ Time Frame: Serious Adverse Events (SAEs) are continually assessed from Screening up to the end of the 30 day FU period. ]
    To investigate the safety and tolerability of AZD4547. A SAE (Serious Adverse Event) is and AE (adverse Event) which fulfills one of the following criteria that the PI assesses closely such as results in death, immediately life-threatening, requires hospitalisation or prolongation of, results in significant disability, results in birth defect, may jepardise the patient or require intervention to prevent any of the previous outcomes.

  6. Number of Participants With at Least 1 Causally Related SAE [ Time Frame: SAEs are continually monitored from screening to end of 30 FU period ]
    To investigate the safety and tolerability of AZD4547: SAEs are assessed and deemed as causally related or not to AZD4547


Secondary Outcome Measures :
  1. AUC(0-infinity) [ Time Frame: PK samples out to 96 hours "0 to 96 hours post-dose" after single dose (in parts A & B only). Steady state PK profile 3 weeks after the start of BD dosing. ]
    To characterise the pharmacokinetics (PK) of AZD4547 following a single administration and at steady state after dosing when given orally.

  2. Tumour Response (Best Objective Response) - Number of Patients With a Confirmed Response of Partial Response (PR) or Confirmed Response (CR) [ Time Frame: Baseline assessment, then assessment every 6 weeks after start of treatment until objective disease progression. ]
    To obtain a preliminary assessment of the anti tumour activity of AZD4547 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1. Objective response = CR + PR; CR=disappearance of all target lesions and PR is >=30% reduction in sum of longest diameter of target lesions

  3. Cmax (ng/mL) [ Time Frame: PK samples out to 96 hours "0-96 hours post dose" after single dose (in parts A & B only). Steady state PK profile 3 weeks after the start of BD dosing. ]
    To characterise the pharmacokinetics (PK) of AZD4547 following a single administration and at steady state after dosing when given orally.

  4. Css,Max (ng/mL) [ Time Frame: PK samples out to 96 hours "0-96 hours post-dose" after single dose (in parts A & B only). Steady state PK profile 3 weeks after the start of BD dosing. ]
    To characterise the pharmacokinetics (PK) of AZD4547 following a single administration and at steady state after dosing when given orally.

  5. AUC,ss(0-infinity) [ Time Frame: PK samples out to 96 hours "0-96 hours post dose" after single dose (in parts A & B only). Steady state PK profile 3 weeks after the start of BD dosing. ]
    To characterise the pharmacokinetics (PK) of AZD4547 following a single administration and at steady state after dosing when given orally.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 149 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Minimum life expectancy of 12 weeks
  • The presence of a solid, malignant tumour that is resistance to standard therapies or for which no standard therapies exist
  • In the expansion for the study patients must have a tumour at least 1cm in size that can be measure using a CT or MRI scan, and provide a tumour sample to the sponsor company for testing of FGFR1 and/or 2 amplification
  • Expansion, 5 groups of advanced cancer
  • Solid tumours,FGFR1 and/or FGFR2 gene amplified
  • Squamous NSCLC, FGFR1 gene low & high amplified
  • Gastric adenocarcinoma, including the lower oesophagus/gastro-oesophageal junction, FGFR2 gene low & high amplified
  • Aged at least 25 years

Exclusion Criteria:

  • Treatment with any other chemotherapy, immunotherapy or anticancer agents within 3 weeks before the first dose of study
  • An inability to be able to take the study medication
  • A bad reaction to AZD4547 or any drugs similar to it in structure or class.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00979134


Locations
Layout table for location information
United States, California
Research Site
Stanford, California, United States, 94305
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06520
United States, Michigan
Research Site
Detroit, Michigan, United States, 48201
United States, New York
Research Site
New York, New York, United States, 10021
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19111
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37232
United States, Texas
Research Site
Houston, Texas, United States, 77030
France
Research Site
Pierre Benite, France, 69495
Research Site
Villejuif, France, 94805
Germany
Research Site
Frankfurt, Germany, 60488
Research Site
Freiburg, Germany, 79106
Research Site
Köln, Germany, 50924
Italy
Research Site
Napoli, Italy, 80131
Research Site
Rozzano, Italy, 20089
Netherlands
Research Site
Amsterdam, Netherlands, 1066 CX
Research Site
Rotterdam, Netherlands, 3015 CE
Spain
Research Site
Badajoz, Spain, 06008
Research Site
Majadahonda, Spain, 28222
Research Site
Valencia, Spain, 46010
Research Site
Valencia, Spain, 46026
United Kingdom
Research Site
Birmingham, United Kingdom, B9 5SS
Research Site
Edinburgh, United Kingdom, EH4 2XU
Research Site
Glasgow, United Kingdom, G12 0YN
Research Site
London, United Kingdom, W12 0NN
Research Site
London, United Kingdom, W1G 6AD
Research Site
Manchester, United Kingdom, M20 4BX
Research Site
Newcastle upon Tyne, United Kingdom, NE7 7DN
Research Site
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Fabrice André, Dr Institut de cancérologie Gustave Roussy
Study Director: Donal Landers, Dr AstraZeneca
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00979134    
Other Study ID Numbers: D2610C00001
First Posted: September 17, 2009    Key Record Dates
Results First Posted: March 15, 2019
Last Update Posted: March 15, 2019
Last Verified: November 2018
Keywords provided by AstraZeneca:
Cancer
Tumour
Advanced Solid Malignancies
 FGFR
Squamous NSCLC
Gastric adenocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms